Oral buflomedil in diabetic background retinopathy: results of a preliminary controlled study.
Twenty insulin-dependent diabetic patients with signs of background retinopathy were given Buflomedil 600 mg/day orally or placebo in a randomized double-blind trial for a 6-month period. A larger number of patients had their retinal condition deteriorating in the placebo group and this finding is an indication for pursuing investigations on a larger scale in this direction.
D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000473:pathology; D004311:Double-Blind Method; D004341:Drug Evaluation; D005451:Fluorescein Angiography; D006801:Humans; D008875:Middle Aged; D011759:Pyrrolidines / Q000627:therapeutic use*; D011897:Random Allocation; D014665:Vasodilator Agents / Q000627:therapeutic use*
D011759:Pyrrolidines; D014665:Vasodilator Agents; C010651:buflomedil